The Global market for Lung Cancer Therapeutics is expected to reach $9.01 billion by the end of 2021 growing at a CAGR of around 6% from 2016 to 2021. Lung Cancer is the lethal lung tumor portrayed by the undisciplined growth of cells in the lung tissues. Cigarette smoking is the principal risk factor for the development of lung cancer. Prolonged exposure to tobacco smoke can also cause lung cancer. The interpretation of lung cancer is confirmed by biopsy which is carried out using bronchoscopy or CT-guidance. The two different types of lung cancer are small cell lung cancer & non-small cell lung cancer. Treatment of lung cancer can be done by chemotherapy, radiotherapy, surgery, etc.
The largest number of cancer deaths in both men and women is because of lung cancer. The lung cancer therapeutics market is segmented on the basis of Chemotherapy, Drugs, Radiotherapy (External beam radiotherapy, Internal radiotherapy and Systemic radiotherapy) and Region (North America, Europe, Asia Pacific and Rest of the World).
Government funding in the field of research and development of new drugs, increasing pollution due to rapid industrialization and rise in the number of smokers are some of the reasons driving the growth of the market.
Large number of players in the market and in turn large number of drugs available in the market are the major constraints faced by the market.
What the report offers: